Top Suppliers:I want be here

2230914-84-6

2230914-84-6 structure
2230914-84-6 structure
  • Name: YM281
  • Chemical Name: YM281
  • CAS Number: 2230914-84-6
  • Molecular Formula: C56H71N7O9S
  • Molecular Weight: 1018.27
  • Catalog: Signaling Pathways Apoptosis Apoptosis
  • Create Date: 2022-06-17 13:18:53
  • Modify Date: 2024-01-13 16:30:17
  • YM281 is a potent EZH2 inhibitor. YM281 induces cell apoptosis and cell cycle arrest at the G0/G1 phase. YM281 shows antitumor effects in vivo. YM281 has the potential for the research of lymphoma[1].

Name YM281
Description YM281 is a potent EZH2 inhibitor. YM281 induces cell apoptosis and cell cycle arrest at the G0/G1 phase. YM281 shows antitumor effects in vivo. YM281 has the potential for the research of lymphoma[1].
Related Catalog
In Vitro YM281 (compound V2) (0-6 µM; 0-48 h) decreases the EZH2 protein level and the PRC2 (polycomb repressive complex 2) complex through the VHL (vonHippel−Lindau)-dependent ubiquitin-proteasome system[1]. YM281 (0-10 µM; 24 h) shows anticancer effects in lymphoma cells[1]. YM281 (0-5 µM) induces cell apoptosis and cell cycle arrest at the G0/G1 phase[1]. YM281 (0-5 µM; 24 h) increases the activity of caspase-3 and -7 and meanwhile reduces the cell viability in primary lymphoma cells[1]. Western Blot Analysis[1] Cell Line: SU-DHL-2, 22Rv1 cells Concentration: 0-6 µM Incubation Time: 0-48 h Result: Abrogated both the EZH2 protein level and the H3K27me3 degree in a concentration-dependent manner in 24 h, had no significant effect on the protein level of EZH1,and significantly increased the expression of EZH2 ubiquitination. Cell Viability Assay[1] Cell Line: SU-DHL-2, SU-DHL-4, SU-DHL-6 cells Concentration: 0-10 µM Incubation Time: 24 h Result: Induced nearly complete cell viability inhibition. Cell Cycle Analysis[1] Cell Line: SU-DHL-6 cells Concentration: 1, 3, 5 µM Incubation Time: 24 h Result: Induced cell cycle arrest at the G0/G1 phase and a profound sub-G1 population increasein a concentration-dependent manner. Apoptosis Analysis[1] Cell Line: SU-DHL-6 cells Concentration: 0-5 µM Incubation Time: 48 h Result: Significantly increased the expression of cleaved caspase-3 and PARP.
In Vivo YM281 (80, 100 mg/kg; i.v.; 6 times for 3 weeks) shows antitumor effects and significantly reduces the expression of EZH2 protein and H3K27me3 levels[1]. Animal Model: Balb/c nude mice (SU-DHL-6 xenograft model)[1] Dosage: 80 mg/kg Administration: I.v.; 6 times for 3 weeks Result: Remarkably suppressed the tumor volume and significantly reduced the EZH2 protein and H3K27me3 levels. Animal Model: Balb/c nude mice (Jeko-1 xenograft model)[1] Dosage: 100 mg/kg Administration: I.v.; 6 times for 3 weeks Result: Shows anti-tumor effects with the significantly reduced the expression of EZH2 protein and H3K27me3 levels.
References

[1]. Tu Y,et al. Design, Synthesis, and Evaluation of VHL-Based EZH2 Degraders to Enhance Therapeutic Activity against Lymphoma. J Med Chem. 2021 Jul 22;64(14):10167-10184.

Molecular Formula C56H71N7O9S
Molecular Weight 1018.27
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.